TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
←
▶ 28:45 · AI Geopolitics & Export Controls · Lonsdale: China systematically stealing U.S. biotech IP via patent office and talent, FDA slowness exacerbates disadvantage
episode briefing
Bloomberg Tech

AI Selloff, Apple vs. OpenAI & the Future of Defense Tech | Bloomberg Tech 7/13/2026

2026-07-13 · 24 company · 13 thematic
sentiment
18 bull4 bear2 neu
speakers
chey tae-won

Chey Tae-won leads SK Group, South Korea's second-largest conglomerate, and serves as chairman of SK Hynix, a major memory chipmaker.

joe lonsdale

Joe Lonsdale hosts American Optimists. He co-founded Palantir Technologies and founded venture firm 8VC. He previously hired Scott Wu at an early company and references his experience building Palantir's forward-deployed engineer model and government technology partnerships.

brendan carr

Brendan Carr leads the FCC, focusing on spectrum policy, space economy regulation, and broadband deployment.

mark gurman

Managing editor for Bloomberg's consumer technology team and chief correspondent covering Apple and consumer hardware. He reports on product strategy, devices, and the technology supply chain.

now playing · AI Geopolitics & Export Controls
Memory & Storagetailwindscore 7/10unknown
Memory makers locking in multi-year deals to de-cyclicalize business amid AI chip shortage
SK Hynix and Micron are using the AI-driven HBM shortage to secure multi-year supply agreements, attempting to transform the historically cyclical memory market into a more structural, less…
AI Hardware & Chip Architecturemixedscore 7/10unknown
Nvidia's AI chip dominance faces long-term pressure from custom silicon and memory innovation
While Nvidia dominates AI chips today, competitors like Google and startups are developing architectures that use different memory types or less memory, creating long-term competitive risk.
Memory & Storageheadwindscore 6/10unknown
Analyst warns correction underway in memory stocks, downside risks prevail amid extreme volatility
The 15% drop in SK Hynix reflects profit-taking and speculative leveraged ETF trading; correction is underway and downside risks dominate while volatility remains elevated.
Space Economytailwindscore 8/10brendan carr
FCC accelerates space economy approvals, targeting orbital data centers and direct-to-device leadership
The FCC is moving to an assembly-line approval model for space applications, cutting backlog by half, and aims to establish two to three US direct-to-device providers to lead globally, bene…
Space Economytailwindscore 7/10brendan carr
FCC Chair Carr: Assembly-line approval mindset for orbital data centers and direct-to-device, creating 440MHz super-band for 5G/6G
The FCC is shifting to an assembly-line approval process for space applications, cutting backlog by half, and enabling direct-to-device satellite connectivity with new spectrum allocations…
Tech Regulation & Antitrustheadwindscore 6/10mark gurman
Apple's trade secret lawsuit against OpenAI chills AI talent mobility
Apple's aggressive litigation against OpenAI for recruiting former employees will deter talent flows between major AI labs, potentially slowing cross-pollination.
AI Geopolitics & Export Controlsheadwindscore 8/10joe lonsdale
Lonsdale: China systematically stealing U.S. biotech IP via patent office and talent, FDA slowness exacerbates disadvantage
China has captured over one-third of global therapeutics development by stealing U.S. IP through patent office exploitation and talent transfer, while U.S. FDA delays (700 days vs 90 days f…
AI Drug Discoverymixedscore 7/10joe lonsdale
AI driving biotech breakthroughs in bone marrow grafts and antibodies, but China IP theft threatens investment returns
AI is enabling major biotech advances like bone marrow graft alternatives and antibody platforms, but the inability to protect IP from Chinese theft undermines the profitability of US biote…
AI Drug Discoverytailwindscore 7/10joe lonsdale
Lonsdale: 8VC portfolio advancing AI-driven antibody platforms and bone marrow grafts through clinical phases rapidly
8VC's biotech portfolio companies are achieving rapid clinical progress (Phase 1-3) with AI-enabled antibody platforms and bone marrow graft technologies with autoimmune applications, but r…
Tech Regulation & Antitrustheadwindscore 7/10joe lonsdale
Lonsdale calls FDA an unaccountable 'mafia' slowing biotech, advocates multiple competing regulatory bodies
The FDA's unchecked power and 700-day approval timelines are a major bottleneck for US biotech competitiveness; Lonsdale proposes multiple competing regulatory bodies to accelerate drug dev…
Defense Techtailwindscore 8/10joe lonsdale
Lonsdale: Pentagon culture shifting toward startup competition, primes losing grip as drones and electronic warfare advance
The Pentagon has undergone a cultural shift over the past 5-6 years, recognizing that startups like SpaceX and Anduril deliver 10x better solutions at lower cost, forcing primes to compete;…
Venture Capitaltailwindscore 7/10joe lonsdale
8VC's $1.5B fund reflects accelerated venture pace, holding defense and AI winners long-term
Venture capital is seeing unprecedented markup velocity with companies doubling revenue quarterly; 8VC plans to hold its best defense and AI positions indefinitely rather than exit.
Venture Capitaltailwindscore 7/10joe lonsdale
Lonsdale: 8VC closes $1.5B fund, 30% allocated to company creation, portfolio growing 5-10x annually
8VC's new $1.5B fund (equivalent to $400M a decade ago) deploys 30% into company creation, with portfolio companies growing 5-10x per year, reflecting accelerated pace of value creation in…